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Abstract
The emergence of multidrug-resistant bacteria has encouraged vigorous efforts to develop
antimicrobial agents with new mechanisms of action. Ribonucleotide reductase (RNR) is a
key enzyme in DNA replication that acts by converting ribonucleotides into the correspond-
ing deoxyribonucleotides, which are the building blocks of DNA replication and repair. RNR
has been extensively studied as an ideal target for DNA inhibition, and several drugs that
are already available on the market are used for anticancer and antiviral activity. However,
the high toxicity of these current drugs to eukaryotic cells does not permit their use as anti-
bacterial agents. Here, we present a radical scavenger compound that inhibited bacterial
RNR, and the compound's activity as an antibacterial agent together with its toxicity in eu-
karyotic cells were evaluated. First, the efficacy of N-methyl-hydroxylamine (M-HA) in inhib-
iting the growth of different Gram-positive and Gram-negative bacteria was demonstrated,
and no effect on eukaryotic cells was observed. M-HA showed remarkable efficacy against
Mycobacterium bovis BCG and Pseudomonas aeruginosa. Thus, given the M-HA activity
against these two bacteria, our results showed that M-HA has intracellular antimycobacter-
ial activity against BCG-infected macrophages, and it is efficacious in partially disassembl-
ing and inhibiting the further formation of P. aeruginosa biofilms. Furthermore, M-HA and
ciprofloxacin showed a synergistic effect that caused a massive reduction in a P. aeruginosa
biofilm. Overall, our results suggest the vast potential of M-HA as an antibacterial agent,
which acts by specifically targeting a bacterial RNR enzyme.
Introduction
Infectious diseases constitute a tenacious and major public health problem worldwide. For
many years, antibiotic-resistant pathogens have been recognized as one of the primary threats
to human survival, and some experts predict a return to the pre-antibiotic era. The emergence
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and increasing prevalence of bacterial strains that are resistant to available antibiotics urge the
discovery of new therapeutic approaches [1]. An equally alarming decline has occurred in the
research and development of new antibiotics to address the threat. Certain virulence factors
have been shown to be potential targets for drug design and therapeutic intervention, and new
insights are crucial for exploiting others [2, 3].
Bacterial DNA synthesis represents an attractive field for the discovery of new antibacterial
targets because of remarkable differences from the eukaryotic system. During the course of in-
fection, bacteria need to multiply inside the body, and they require active DNA synthesis to
multiply. The key enzyme that provides the nucleotide precursors for DNA replication and re-
pair are RiboNucleotide Reductases (RNRs). Three major classes of this enzyme are known
(class I, II and III). Class I RNRs (subclasses Ia (nrdAB) and Ib (nrdEF)) carry a stable tyrosyl
radical and are oxygen-dependent and thus, they only work under aerobic conditions; class II
RNRs (nrdJ) require the vitamin B12 cofactor 5’-deoxyadenosylcobalamin and are oxygen-in-
dependent. Class III RNRs (nrdD, with their cognate nrdG activase) carry a stable glycyl radi-
cal, are oxygen-sensitive and only work under strict anaerobic conditions [4–8]. Eukaryotes
only encode for one RNR class (Ia), but microorganisms have the ability to encode all possible
RNR combinations [9, 10]. For this reason, RNRs could be considered a good antimicrobial
target candidate to inhibit bacterial growth because they present substantial differences relative
to their eukaryote counterparts [11, 12].
Several potential RNR inhibitors were reported, which included the following: free radical
scavengers, iron chelators and substrate analogs [13–16]. Radical scavenger agents main mech-
anism of action is elicited through the inhibition of the RNR enzymes by scavenging the tyrosyl
free radical (on the small class I subunits; NrdB and NrdF) that is required for the catalytic pro-
cess [17]. These compounds have been shown to be useful for cancer treatment [18, 19]. One
known family of radical scavenger compounds are derivatives from the hydroxylamine (HA)
moiety, specifically hydroxyurea (HU), which is most commonly used for cancer treatment
[18]. In fact, these compounds effectively inhibit the RNR of eukaryotic cells [19], reducing the
possibility of using these drugs to treat bacterial infections without interfering in human RNR.
The modes by which different radical scavenger compounds interact in response to purified
RNR enzyme were studied in our previous works [11, 12]. One compound, namely N-methyl-
hydroxylamine (M-HA), was a highly active inhibitor of purified Bacillus anthracis RNR en-
zyme without interfering with the murine RNR enzyme. Although M-HA is promising as an
antibacterial agent, its potential antimicrobial activity has not been evaluated.
In the present work, we aimed to explore the capacity of M-HA to inhibit the growth of clin-
ically interesting Gram-positive (Staphylococcus aureus, Streptococcus sanguinis, Streptococcus
mutans andMycobacterium) and Gram-negative (Pseudomonas aeruginosa and Burkholderia
cenocepacia) bacteria. Next, we investigated the effects of M-HA antibacterial activity on intra-
cellular bacterial growth and biofilm-forming bacteria. Finally, the possible synergic activity of
M-HA and other antimicrobials was evaluated.
Materials and Methods
Bacterial strains and mammalian cell line
Streptococcus mutans (ATCC 25175) and Streptococcus sanguinis (ATCC 10556) were grown
in Todd-Hewitt broth (Oxoid) at 37°C. Staphylococcus aureus (ATCC 12600), Pseudomonas
aeruginosa PAO1 (ATCC 15692) and Burkholderia cenocepacia J2315 (ATCC BAA-245) were
grown in trypticase soy broth (TSB) or trypticase soy agar (TSA) (Sharlab, Barcelona, Spain) at
37°C.Mycobacterium bovis Bacillus Calmette-Guérin (BCG) substrain Connaught (ATCC
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35745) was grown on Middlebrook 7H10 agar (Difco Laboratories, Surrey, UK) supplemented
with 10% oleic-albumin-dextrose-catalase enrichment medium at 37°C for 2 weeks.
A murine macrophage J774A.1 cell line (DSMZ ACC 170) was maintained in Dulbecco’s
Modified Eagle’s medium (DMEM) with L-glutamine (Gibco BRL, Grand Island, NY) supple-
mented with 10% heat-inactivated fetal bovine serum (FBS, Lonza Ltd., Switzerland) contain-
ing 100 U/ml penicillin G (Lab ERN, Barcelona, Spain) and 100 μg/ml streptomycin (Lab Reig
Jofre, Barcelona, Spain) (complete medium) at 37°C in a humidified atmosphere with 5% CO2.
Radical scavenger compounds
The hydroxylamine-bearing compounds used in this work were hydroxyurea (HU;M=
76.05 g/mol) (Sigma-Aldrich), hydroxylamine (HA;M = 33.03 g/mol) (Sigma Aldrich)
and N-methyl-hydroxylamine (M-HA;M= 83.52 g/mol) (Acros Organics). Solutions were
freshly prepared in PBS and filtered through a 0.22-μm pore-size filter (Millipore) before each
experiment.
Antibacterial susceptibility testing
To determine the survival of the different strains in the presence of different radical scavengers,
each bacterial strain was grown in its specific medium to mid-log phase (A550 0.5) and plated
on solid plates supplemented with different concentrations of each compound.
In the case of BCG, colonies were scraped fromMiddlebrook 7H10 plates, resuspended in
phosphate-buffered saline (PBS), slightly vortexed with glass beads to dissolve clumps, and al-
lowed to settle for 30 minutes. The supernatant was diluted in PBS and adjusted to 1.0 McFar-
land standard. Serial dilutions were then plated on solid plates containing freshly prepared
compounds at the indicated concentrations. Colony-forming units (cfu) were counted after
growing.
Inhibitory concentration 50% (MIC50) was defined as the compound concentration that re-
duced bacterial growth (cfu) by 50%, and MIC100 was defined as the lowest concentration of
drug that visibly inhibited bacterial growth by 100%.
Determining mammalian cytotoxicity
Murine J774 macrophages (6x104 per well) were seeded onto 48-well tissue culture plates in
complete medium without antibiotics in the presence of different doses of HU, HA and M-HA,
or left untreated. After 24, 72 and 120 h of exposure to the different compounds, culture super-
natants were removed and cell viability was assessed by using a 3-[4,5-dimethylthiazol-2-yl]-
2,5-diphenyltetrazolium bromide (MTT) colorimetric assay (Sigma Aldrich) (20). Absorbance
was measured at 550 nm with an ELISA reader (Infinite M200 Microplate Reader, Tecan). The
results were expressed as a percentage of cell survival relative to untreated cells. Each experi-
ment was repeated at least three times.
In another set of experiments, cells were washed at 24 hours after adding the compounds
for the first time, and new, freshly made compounds were added. Cell viability was measured
each 24 hours as described above.
The 50% cytotoxicity inhibitory concentration (CC50) of each drug was determined from
dose-response curves by using Graph Pad Prism v6. The selectivity index (SI) (SI = CC50/
MIC50) was calculated on the basis of the CC50 and MIC50 values as determined after 24 h
of exposure.
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The anti-BCG intracellular activity of the different compounds
For the infection experiments, BCG suspensions were adjusted to a 1.0 McFarland standard
and centrifuged at 2000 g for 10 minutes. The bacterial pellets were re-suspended in complete
medium without antibiotics and were further subjected to three consecutive 30 second pulses
(45 W) in an ultrasonic water bath to obtain a predominantly single bacterial cell suspension.
Murine J774 macrophages (3x104 per well) were seeded onto 48-well plates in complete me-
dium without antibiotics. Twenty-four hours later, they were infected with BCG at a multiplici-
ty of infection (MOI) of 10 for three hours as previously described [20]. The MOI was
confirmed by plating serial dilutions of the inoculum on solid media. After three hours, cells
were washed to remove extracellular bacteria and incubated with fresh complete medium plus
different doses of HU, HA, and M-HA, at 37°C in a 5% CO2 atmosphere. All infections were
performed in triplicate. The cell culture supernatants were removed, macrophages were lysed,
and bacterial counts were determined by plating serial dilutions on Middlebrook 7H10 plates
at different time points after infection (24, 72, and 120 h) [20]. Non-infected control cultures
were always included and all experiments were repeated at least three times.
Cytokine analysis and nitric oxide (NO) production
Cell culture supernatants were collected at different time points as indicated above in both ex-
periment types for macrophage cell viability and intracellular BCG susceptibility to the com-
pounds. Interleukin (IL)-10, IL-12 and tumor necrosis factor (TNF)-α levels were determined
by using commercially available enzyme-linked immunosorbent assays (ELISA) (IL-10 and IL-
12p40 fromMabtech AB, Nacka Strand, Sweden; and TNF-α from R&D Systems Inc., Minne-
apolis, MN, USA) according to the manufacturer’s instructions. All samples were assayed
in duplicate.
The NO production was assessed by measuring nitrite concentrations with the Griess reac-
tion (Sigma).
Viability test analysis
An overnight culture of P. aeruginosa PAO1 was diluted in fresh LB medium and grown to the
beginning of exponential phase (A550* 0.3) to which different concentrations of radical scav-
enger compounds were added. After 3 or 24 hours of incubation at 37°C, the cells were stained
by using the LIVE/DEAD BactLight viability kit (Life Technologies) for 15 minutes at room
temperature in the dark. Fluorescent bacteria were visualized with a Nikon E600 microscope
(Nikon) coupled with a DP72 Olympus camera.
Viable cell counts in biofilm inhibition after radical scavenger treatment
To investigate the anti-biofilm activity of the different radical scavengers alone or in combina-
tion with ciprofloxacin, P. aeruginosa PAO1 biofilms were grown on microtiter plates and a
previously described protocol was followed [21]. An overnight-grown culture of P. aeruginosa
in TSB was diluted 1:100 in sterile TSB medium supplemented with 0.2% glucose and added to
a 96-well microtiter plate with pegs (Nunc-TSP, Thermo Scientific) (200-μl each well). After
24–48 h of incubation at 37°C in a humidified chamber, the culture supernatant was discarded
and the pegs were washed three times with sterile PBS to remove non-adherent cells. After
being rinsed, the biofilms were treated with different radical scavenger concentrations alone or
in combination with ciprofloxacin. After 24 h of treatment, the pegs were transferred to a new
plate that had been rinsed with PBS. Adherent bacteria were first fixed with 200 μl of methanol
for 10 min and then stained with crystal violet (1%) for 10 min. Excess crystal violet was
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washed gently with water and the pegs were dried in air for 5 min. The dye that was bound to
the cells was dissolved with 150 μl of ethanol 95%, centrifuged at 2000 rpm for 10 min, and
read at 570 nm with a microplate reader (Infinite M200).
Biofilm culture in flow cell system and confocal microscopy analysis
To prepare biofilms developed under continuous flow, P. aeruginosa cells (5x105 cfu/ml) were
cultured in LB medium at 25°C in flow chambers with channel dimension of 1x4x40 mm as de-
scribed previously [22]. After 96 h of culture, formed biofilms were treated with 40 μg/ml of
HA, HU or M-HA, and LB medium was used alone in the control sample. After 24 h of treat-
ment at 25°C, biofilms were stained with 5 μM SYTO 9 at room temperature in the dark for 30
min, according to the specifications of the LIVE/DEAD BacLight Bacterial Viability kit (Molec-
ular Probes, Invitrogen).
Confocal scanning laser microscopy of the biofilms was performed with a Leica TCS-SP5
confocal scanning laser microscope (Leica Microsystems, Wetzlar, Germany), with an excita-
tion wavelength of 477 for SYTO9. To measure biofilm thickness, sections were scanned and
Z-stacks were acquired at z step-size of 0.388 μm. Field size was 456 μm x 456 μm at 20X mag-
nification. Microscope images were further processed with ImageJ analysis software (National
Institute of Health, USA) and COMSTAT 2 software, specific for biofilm quantitative analysis
[23].
Statistical analyses
Data were presented as the means ± standard deviation (SD). The statistical significance of dif-
ferences between cytokine levels and BCG growth inhibition using the different radical scaven-
ger compounds was assessed by using Student’s t-tests (SigmaStat, SPSS, Chicago, IL).
Differences were considered significant when P< 0.05. All statistical procedures were per-
formed with SPSS 15.0 software (SPSS Inc., Chicago, IL).
Results
M-HA showed greater antibacterial activity than HU and HA radical
scavengers
The antibacterial activity of three radical scavengers (HU, HA and M-HA) was evaluated
against four Gram-positive bacteria (S. aureus, S.mutans, S. sanguinis andM. bovis BCG) and
two Gram-negative bacteria (P. aeruginosa and B. cenocepacia). As shown in Table 1, the HU
compound exhibited moderate activity against S. aureus, S.mutans and S. sanguinis (200–
330 μg/mL) and high growth inhibitory activity against P. aeruginosa,M. bovis and B. cenoce-
pacia (7.6 to 13 μg/mL). HA showed better growth inhibitory activity relative to HU in all test-
ed bacteria (2 to 52 μg/mL). M-HA was highly active inM. bovis BCG and P. aeruginosa
cultures, with a 1.5 to 4.5-fold lower MIC50 than HU and HA. In BCG cultures, 7.5 to 43 times
lower concentrations of M-HA (MIC50 = 1.9 μg/mL) were needed to obtain the same results as
the other bacteria cultures (from 14.2 μg/mL for B. cenocepacia to 81.9 μg/mL for S. sanguinis)
(Table 1).
To investigate the mechanisms through which M-HA inhibits bacteria growth, we specifi-
cally stained bacteria with the Live/Dead BactLight bacterial viability assay (Invitrogen). As
shown in Fig. 1, the different radical scavengers (at a MIC50 concentration) did not apparently
modify the bacterial membrane integrity after 3 hours of treatment because all of them were
stained green. After 24 h of treatment, the proportion of non-viable cells (red cells) increased,
especially when treated with M-HA.
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M-HA does not affect eukaryotic cell growth
The antiproliferative activity of the three radical scavengers was evaluated against murine J744
macrophages by MTT staining. As expected, HU and HA interfere with macrophage prolifera-
tion even when low concentrations are used (Fig. 2). Only the lowest dose of HA (10 μg/ml)
permits macrophage growth. By contrast, concentrations of up to 250 μg/ml M-HA do not in-
hibit macrophage proliferation (Fig. 2). The same results were obtained when culture medium
plus radical scavenger compounds were renewed every 24 hours (data not shown), and even if
the cells were treated for up to 120 hours (data not shown). As shown in Table 1, a cytotoxic
concentration (CC50) is observed for M-HA when doses higher than 250 μg/mL were used.
The selectivity index (SI) was calculated on the basis of the MIC50 and CC50 values that
were determined after 24 h of exposure (Table 1). High SI values were obtained for M-HA in
Mycobacterium and Pseudomonas growth inhibition (SI = 182.6 forM. bovis and 52.5 for P.
Fig 1. P. aeruginosa viability according to the LIVE/DEAD assay after treating with HU, HA, and M-HA. The bacteria were grown with HU (7.6 μg/ml),
HA (8.3 μg/ml), or M-HA (6.7 μg/ml) for 3 and 24 hours and stained with LIVE/DEAD assay. Live cells were green (SYTO 9 dye) and dead cells were red
(propidium iodide dye) under a fluorescent microscope. Magnification, x 1000. HU, hydroxyurea; HA, hydroxylamine; and M-HA, methyl-hydroxylamine.
doi:10.1371/journal.pone.0122049.g001
Table 1. The antibacterial activity of HU, HA and M-HA against Gram-positive and Gram-negative bacteria.
HU μg/ml HA μg/ml M-HA μg/ml
MIC50 MIC100 CC50 SI MIC50 MIC100 CC50 SI MIC50 MIC100 CC50 SI
S. aureus 279.9 >380 25.9 0.09 28.4 <132.2 12.9 0.45 58.5 <334.1 350.8 6
S. mutans 205.3 >1140 25.9 0.13 16.5 <231.4 12.9 0.78 77.7 <584.7 350.8 4.5
S. sanguinis 336.9 >1140 25.9 0.08 51.5 <231.4 12.9 0.25 81.9 <417.6 350.8 4.3
M. bovis BCG 8.36 >380 25.9 3.1 2.6 <16.5 12.9 4.96 1.9 <41.8 350.8 184.6
P. aeruginosa 7.6 <41.8 25.9 3.4 8.3 <66.1 12.9 1.55 6.7 <108.6 350.8 52.4
B. cenocepacia 12.9 >129.3 25.9 2 2.6 >66.1 12.9 4.96 14.2 >142 350.8 24.7
The growth inhibition of different bacteria after culturing them in HU-, HA-, or M-HA-supplemented media. The data are representative of one of at least
three independent experiments. HU, hydroxyurea; HA, hydroxylamine; M-HA, methyl-hydroxylamine; MIC50, 50% inhibitory concentration; MIC100, 100%
inhibitory concentration; CC50, 50% cytotoxicity inhibitory concentration; and SI, selectivity index (SI = CC50/MIC50).
doi:10.1371/journal.pone.0122049.t001
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aeruginosa), which were much higher than the SI obtained with HA or HU (SI from 0.08 to
4.9).
M-HA shows intracellular antimycobacterial activity
In view of the results shown in Table 1, M-HA seems to be a promising antimycobacterial can-
didate because mycobacteria are the intracellular pathogens for which we aimed to demon-
strate activity in infected macrophages. As shown in Fig. 3A,M. bovis BCG viability was
diminished when infected macrophages were incubated in the presence of the different radical
scavenger compounds related to untreated wells. At 72 hours post-infection, HU triggers a
BCG growth inhibition of approximately 50%, but only HA treatments exhibited better inhibi-
tion values when the dose was greater than 35 μg/ml. As explained before, this finding also cor-
responds to a concomitantly drastic reduction in macrophage viability (see Table 1, CC and
Fig. 2). By contrast, M-HA showed enhanced intracellularM. bovis BCG growth inhibition in
comparison with that of HU or HA at a range of concentrations that were not toxic for eukary-
otic cells between 74.6% BCG survival at 8 mg/ml and 42.6% at 125 mg/ml (Fig. 3A). Moreover,
the M-HA intracellular antimycobacterial activity improved when the culture medium was
Fig 2. Dose-response curves for HU, HA andM-HA treatments of murinemacrophages. The level of growth alteration for J774 macrophages that were
treated with different doses of radical scavenger compounds at 72 hours post-treatment. Cell viability was measured by using an MTT assay. Values
represent the means ± standard deviation (SD) of triplicate cultures. The data are representative of one of at least three independent experiments. (*,
P< 0.05 vs. non-treated cells). HU, hydroxyurea; HA, hydroxylamine; and M-HA, methyl-hydroxylamine.
doi:10.1371/journal.pone.0122049.g002
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Fig 3. The intracellular BCG growth inhibition of macrophages treated with different doses of HU, HA and M-HA. The effects of different doses of
radical scavenger compounds on the intracellular viability of BCG at 72 hours post-infection. A) Compounds were added 3 hours after infection B)
Compounds were renewed every 24 hours after infection. The results are expressed as the means ± standard deviation (SD) of triplicate wells in percentages
of inhibition with respect to non-treated cells. The data are representative of one of at least two independent experiments where statistically significant
M-HA Acts as a Ribonucleotide Reductase Inhibitor
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changed every 24 hours by adding freshly prepared compounds, and values of up to 13% BCG
survival were reached (Fig. 3B). In absolute numbers, this finding represents up to a one log re-
duction, i.e., at 72 hours post-infection, an M-HA concentration of 82 mg/ml was reduced
from 6.3x104 (untreated wells) to 8.4x103 viable BCG cells (cfu). Similar values were observed
in both cases (replacing or not replacing the compounds every 24 hours) at 120 hours post-in-
fection (data not shown).
Increased TNF production by M-HA
We investigated the production of two bactericidal products that are able to kill intracellular
BCG, namely TNF-α and NO [24], when the macrophages were infected with BCG and treated
with the different radical scavenger compounds. As shown in Fig. 4, M-HA-treated macro-
phages produce higher TNF-α values at 24 hours post-infection than untreated cells (Fig. 4A).
The highest amount of cytokine production was observed when cells were treated with high
concentrations of M-HA (Fig. 4A). The amount of cytokine production did not increase after
longer periods of incubation (72 or 120 hours after infection) (data not shown). When TNF-α
production was evaluated in non-infected cultures, similar values were obtained in radical scav-
enger-treated and non-treated macrophages (data not shown).
Low but detectable amounts of NO production between 1 and 3 μM of NO were found in
both BCG-infected radical scavenger-treated and untreated macrophages. No significant differ-
ences were observed between HA, HU and M-HA-treated macrophages. These data are consis-
tent with previous data from [25].
When the production of IL-10 and IL-12 was studied in BCG-infected macrophages treated
with the different radical scavengers, the results differ between cytokines and treatments.
While IL-10 production was not detected in any case (data not shown), IL-12 production was
significantly increased in HA-treated macrophages in a dose-dependent manner (Fig. 4B). At
the highest HA concentration, however, IL-12 production dramatically diminished, probably
due to the reduced presence of viable macrophages (Fig. 2).
M-HA inhibits P. aeruginosa biofilm formation
As explained previously, good M-HA antibacterial activity was also observed against P. aerugi-
nosa (SI = 52.4). Thus, we further investigated the capacity of M-HA in reducing P. aeruginosa
biofilms because it is one of the most important forms of persistent bacteria and is a character-
istic of chronic P. aeruginosa infections. We used the quantitative microtiter plate method to
determine the effect of the different hydroxylamine derivative compounds on biofilm forma-
tion. A dose-effect concentration was observed for each compound (Fig. 5). At 20.6 μg/ml HA
and 82.5 μg/mL HU and M-HA, P. aeruginosa growth was completely arrested and no biofilm
was formed (Fig. 5).
The M-HA effect on a preformed P. aeruginosa biofilm
Once a biofilm has been established, the cells are extremely resistant against all types of antibi-
otics and detergents and it is often challenging to remove. The effects of the different radical
scavengers on existing P. aeruginosa biofilms were initially assessed using crystal violet-based
biomass staining assay. As Fig. 6 shows, all compounds reduce the amount of biofilm formed,
reaching values of approximately 55%, 90% and 70% reduction from HU, HA, and M-HA,
differences between treated and untreated cells (P< 0.05) for all compounds and concentrations. HU, hydroxyurea; HA, hydroxylamine; and M-HA, methyl-
hydroxylamine.
doi:10.1371/journal.pone.0122049.g003
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Fig 4. TNF-α and IL-12 production as triggered by BCG-infected macrophages that were treated with
different doses of HU, HA andM-HA. J774 macrophages were infected with BCG and treated with different
concentrations of radical scavenger compounds, and TNF-α and IL-12 levels were measured 24 hours post-
infection. The results represent the means ± SD of triplicate preparations with one representative of two
M-HA Acts as a Ribonucleotide Reductase Inhibitor
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respectively, at the highest tested concentrations and three days of treatment. When employing
M-HA concentrations that did not affect eukaryotic cell viability (up to 165 mg/ml), increasing
amounts of compound diminished the established biofilms, indicating that the cells in an
independent experiments. A Mann-Whitney test was performed (*, P< 0.01; versus non-treated
macrophages (control)). HU, hydroxyurea; HA, hydroxylamine; and M-HA, methyl-hydroxylamine.
doi:10.1371/journal.pone.0122049.g004
Fig 5. The inhibition of biofilm formation by different doses of HU, HA and M-HA. The biofilm formation of P. aeruginosa PAO1 was quantified as the
absorbance of crystal violet stain (A570 nm) after being cultured for 24 h in 96-well plates in the presence and absence of the radical scavenger compounds.
The values represent the percentages of biofilm biomass production. The results are expressed as the means ± SD of five replicates from one representative
of three independent experiments. A Student's t-test was performed (**, P< 0.01; versus non-treated biofilms). HU, hydroxyurea; HA, hydroxylamine; and
M-HA, methyl-hydroxylamine.
doi:10.1371/journal.pone.0122049.g005
M-HA Acts as a Ribonucleotide Reductase Inhibitor
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Fig 6. Disassembling the existing P. aeruginosa biofilms by adding HU, HA and M-HA. P. aeruginosa
bacteria were allowed to form biofilms in peg plates for 24 h, the medium was removed and fresh medium
with different concentrations of radical scavenger compounds were changed every 24 hours over three days
(Days 1, 2 and 3). The percentage of biofilm biomass production is represented for each day. The results are
M-HA Acts as a Ribonucleotide Reductase Inhibitor
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existing biofilm can be removed or disaggregated. Moreover, the highest biofilm reductions
under M-HA treatment were found after three days of treatment, with 20% less remaining bio-
film compared with the first day of treatment (Fig. 6). Further, confocal scanning laser micros-
copy of a biofilm grown in a flow cell chamber in the presence of the different radical
scavengers showed significantly reduced biomass and average thickness of the treated samples
(HA, HU and M-HA) compared to the untreated sample (Table 2 and Fig. 7).
Synergic effects on biofilm reduction by ciprofloxacin plus M-HA
The capacity to remove a pre-existing biofilm was evaluated when treating with ciprofloxacin
in combination with M-HA. Ciprofloxacin alone showed a dose-dependent effect on P. aerugi-
nosa biofilm reduction (Fig. 8). However, in comparison with treatments that employed cipro-
floxacin alone, the combined use of ciprofloxacin and M-HA was more efficient for removing
pre-existing biofilm, yielding 50% reduction values at ciprofloxacin concentrations of 0.016 or
0.008 μg/ml, and 6.6 or 86 μg/m of M-HA, respectively, was added. (for 5 to 8 times lower con-
centration than ciprofloxacin alone to have the same effect) (Fig. 8).
Discussion
The clinical use of RNR inhibitors has a history of several decades, and this history has demon-
strated that RNR inhibitors have antitumor activity alone or in combination with other drugs
[13, 18, 19]. Among RNR inhibitors, some radical scavenger compounds derived from hydrox-
ylamines such as HU have been used for some types of cancer treatment [18]. Both HA and
HU dramatically affect eukaryotic viability, and thus little interest has been aroused in studying
these compounds as antimicrobial agents. It remains an important goal to develop a novel HA
derivative with low toxicity and improved cytostatic action especially for treating bacterial in-
fections. We previously demonstrated the capacity of the HA derivative M-HA in inhibiting
RNR enzymatic activity in B. anthracis [11], although its potential as an antimicrobial drug has
not been investigated. When exploring the role of M-HA in inhibiting the growth of a wide
range of pathogenic Gram-positive or Gram-negative bacteria during a comparison of HA and
HU, the intracellular bacterial growth and the formation of biofilms was evaluated.
the means ± SD of three-five replicates from one representative of two independent experiments. A Student's
t-test was performed (*, P< 0.05; versus non-treated biofilms). HU, hydroxyurea; HA, hydroxylamine; and
M-HA, methyl- hydroxylamine.
doi:10.1371/journal.pone.0122049.g006
Table 2. Bioﬁlm parameters of wild-type P. aeruginosa treated with 40 μg/ml HA, HU and M-HA.
Live cells (green)
Biomass (μm3/μm2) Averange thickness (μm)
Untreated 28.9 ±4.7 40.2±3.5
HU (40 μg/ml) 11.9±4.5* 24.2±8.2*
HA (40 μg/ml) 10.7±3.2* 19.4±2.5*
M-HA (40 μg/ml) 20.5±5.9* 30.6±2.9*
Biomass values indicate the amount of living cells inside the bioﬁlm. Values represent the mean ± SD of
three independent experiments. Asterisk denotes signiﬁcant differences compared to non-treated bioﬁlm
(p<0.05, Student’s t-test).
doi:10.1371/journal.pone.0122049.t002
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Our results show that HA and M-HA are more efficacious that HU as antimicrobial agents
for both Gram-positive and Gram-negative bacteria (Table 1). For instance, P. aeruginosa and
M. tuberculosis use an iron containing class I RNR (class Ib) [26, 27] while B. anthracis clearly
uses a manganese class I RNR (Class Ib) [28]. Our results suggest that M-HA is an active inhib-
itor for both iron and manganese forms of RNR.
When eukaryotic cytotoxicity was evaluated, HU and HA exerted high toxicity in murine
macrophage cells (CC50 of 25.8 and 12.9 μg/ml, respectively) as expected (Fig. 2). Our results
are consistent with previous results in which HU and resveratrol (a radical scavenger aromatic
Fig 7. Confocal microscopy of P. aeruginosa biofilms grown on flow cell. The formed biofilms were treated for 24 h with HU, HA and M-HA at 40 μg/ml
final concentration. Each panel shows the maximum Z-projection and the orthogonal views for each stack.
doi:10.1371/journal.pone.0122049.g007
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compound that is not derived from HA) were efficacious against pathogenic bacteria (P. aeru-
ginosa, Propionibacterium acnes, S. aureus, and Enterococcus faecalis) but had high toxicity in
eukaryotic cells as well [29, 30]. However, M-HA showed a highly reduced toxic effect on mac-
rophage culture (CC50 of 351 μg/mL), corroborating the low toxicity of M-HA that was also
found against human lung fibroblasts [31]. Thus, our first results confirm the promising role of
M-HA as an antimicrobial agent.
Because of their small sizes, these compounds would easily cross the cell wall and membrane
and exert their antimicrobial activity directly through RNR enzyme inhibition. In previous
works, we determined that M-HA specifically inactivates the bacterial enzymatic activity of the
essential RNR enzyme by quenching the tyrosyl radical that is necessary for enzymatic activa-
tion, thus making it unable to form dNTPs and blocking DNA synthesis [11]. The exact mode
Fig 8. The synergistic effect of ciprofloxacin and M-HA on the reduction in P. aeruginosa biofilm formation. P. aeruginosa bacteria were allowed to
form biofilms in peg plates for 24 h, the medium was removed and fresh medium with different concentrations of ciprofloxacin with/without M-HA were added.
Biofilm formation (crystal violet stain) was evaluated 24 hours later. The biofilm biomass production percentage is represented here. The results are the
means ± SD of three-five replicates from one representative of two independent experiments. A Student's t-test was performed (*, P< 0.05; **, P< 0.005
versus ciprofloxacin treated biofilms). CPX, ciprofloxacin; and M-HA, methyl-hydroxylamine.
doi:10.1371/journal.pone.0122049.g008
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of M-HA is not completely understood, but some authors hypothesize that this molecule can
interact directly in the places where the tyrosyl radical is formed because of its small size [32].
In terms of HU, which is a bigger molecule than M-HA, it seems that the interaction does not
occur directly where the tyrosyl radical is generated but is more directed at interrupting the cat-
alytic electron transfer pathway of the small subunit at the interface between the interaction be-
tween the small (α) and large RNR (β) subunits [33–35]. This finding could explain why
M-HA was approximately several orders of magnitude more effective at inhibiting bacterial
RNR than HU. Confirmation was established with the use of HA, the smallest HA, with the
highest antimicrobial activity that also presents the highest toxicity because this molecule sure-
ly interacts with and can reach the tyrosyl radical site easily in both prokaryotic and eukaryotic
RNR. Another issue is to understand the precise mechanism of action for the bacterial killing
of radical scavengers after blocking the RNR enzyme. In E. coli [36] HU has been recently
shown to cause increased superoxide production, and together with increased iron uptake, this
increase fuels the formation of hydroxyl radicals that contribute to HU-induced cell death.
Based on the HU analogy, we believe that the M-HA mode of action or bacterial killing might
be similar.
Interestingly, M-HA has the highest therapeutic index for cytotoxicity (SI) for its inhibition
ofM. bovis BCG (182.6 μg/ml), which is 3.5 times that of P. aeruginosa (52.5 μg/ml). Because
of the global relevance of these two agents, we should search for the possible role of M-HA in
treating these agents.
To measure the potential growth inhibitory capacity of these compounds against mycobac-
teria, we selected BCG as a model in murine macrophages. Although there are significant dif-
ferences betweenM. tuberculosis and BCG, they are closer genetically, and previous studies
have demonstrated the validity of BCG for the in vitro evaluation of drug candidates against tu-
berculosis [37, 38]. In our case, a comparison of the BCG RNR primary protein structure
showed 100% shared identity with that of theM. tuberculosis RNR protein, the causative agent
of tuberculosis (see S1 Fig.). This finding indicates a possible identical mode of action for
M-HA on theM. tuberculosis RNR. BCG intracellular kinetics in J774 macrophages has been
very well characterized [25, 39]. Initially, J774 macrophages ingest mycobacteria and internal-
ize BCG cells into phagosomes. An initial killing is observed during the first three days of infec-
tion, and then a stable level of viable BCG can be observed in J774 macrophages. Despite the
fact that BCG does not grow as exponentially inside macrophages asM. tuberculosis does, BCG
is continuously growing and being killed by macrophages [25]. This finding permits the use of
this model for evaluating new drug candidates with the capacity to interfere in mycobacterial
DNA synthesis.
Our results showed that up to 85% of mycobacterial growth inhibition by M-HA occurs at
72 hours post-infection (Fig. 3). In view of the impressive results obtained here, we aimed to go
further in understanding the mechanism. As expected [40], our results showed that BCG-in-
fected macrophages do not induce NO production. Treatment with HA-derivatives did not sig-
nificantly modify these results. However, enhanced TNF-α production, which is another
killing mechanism of macrophages, is observed in M-HA-treated macrophages. The increased
production of TNF-α in BCG-infected M-HA-treated macrophages could be explained by dif-
ferent reasons. On the one hand, BCG-infected J774 macrophages release exosomes that con-
tain mycobacterial antigens such as a 19 kDa antigen or phosphatidyl inositol mannosides
known to induce pro-inflammatory cytokines such as TFN-α by exerting bystander effects on
other cells [41]. The M-HA treatment could induce a higher production of these exosomes
than non-treated macrophages. On the other hand, M-HA could directly induce TNF-α pro-
duction in BCG-infected macrophages. Two reasons led us to support this last option. First,
TNF-α production is observed as early as 24 hours post-infection (Fig. 4), whereas the exosome
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released from BCG-infected J774 macrophages is primarily detected between 48 and 72 hours
post-infection [41]. Second, an M-HA dose-dependent response is observed in TNF-α produc-
tion, leading us to favor the second hypothesis. The fact that TNF production levels in non-in-
fected M-HA-treated macrophages were lower than those detected in M-HA-treated BCG-
infected macrophages indicates that a BCG-infection must be related to the capacity of M-HA
to induce TNF-α production, as was previously described for other drugs [42, 43]. Neverthe-
less, we cannot rule out other possible mechanisms, such as the influence of such radical scav-
engers in other routes related to cytokine production. Supporting this idea, significant IL-12
levels were only detected in BCG-infected HA-treated macrophages. Although in vitro and in
vivo data indicated that HU or HA treatment triggers chemokines and/or cytokines production
[44–48], the mechanism by which these compounds interfere with cytokine-mediated signaling
is also unclear. TNF-α and IL-12 are critical cytokines in the control of mycobacterial infec-
tions [49]. Synergically with IFN-γ, the compounds activate naive macrophages, which in turn
help to control mycobacteria growth. Previous studies demonstrated that TNF-α and IL-12
production is differently regulated in mycobacteria infected macrophages [50]. Thus, our re-
sults provide an initial step to further understand the possible role of cytokines production in
BCG cell growth inhibition as mediated by these radical scavengers.
To our knowledge, this is the first report describing the use of a radical scavenger and more
specifically the first to observe the M-HA effect on mycobacterial inhibition. Among infectious
diseases, tuberculosis (TB) is the leading killer with over two million casualties annually world-
wide. The WHO considers tuberculosis to the most dangerous chronic disease in the world. In
recent years, the emergence and spread of resistantM. tuberculosis strains has fuelled the TB
epidemic by making it more difficult to treat. These results make the M-HA a potentially valu-
able agent, and further analyses must be performed to test it in a combination therapy with ex-
isting, well-known antimycobacterial drugs.
Regarding P. aeruginosa, the primary point of interest is an evaluation of the capacity to re-
duce biofilm formation. Considering that biofilm formation protects bacteria during infections,
such as in chronic wounds, hospital-related pneumonia and bacterial chronic lung infections
[51], the inhibition of biofilm formation by M-HA is a critically important quality as a poten-
tial therapeutic, possibly more so than its anti-microbial activity. Bacterial biofilms generally
become 10–1000 times more resistant to the effects of antimicrobial agents than planktonic
cells [52].
We were able to demonstrate that M-HA is capable of inhibiting P. aeruginosa biofilm for-
mation (for an approximately 60% reduction at 5.2 μg/mL on the third day of continuous treat-
ment); this study compared favorably with other studies that employed different anti-biofilm
strategies [53]. These results were corroborated by growing P. aeruginosa cells to form a con-
tinuous biofilm in flow cells and imaging by laser scanning confocal microscopy (Table 2 and
Fig. 7). Moreover, the combination of M-HA with the well-known antibiotic ciprofloxacin in-
creased the ability to reduce an existing biofilm 10–20 times better than ciprofloxacin or
M-HA alone. Using new and existing antimicrobials may provide a new strategy for bacterial
therapy. Drug combinations would decrease the likelihood of resistance [54]. This finding
demonstrates the feasibility of combined chemotherapy with known antibiotics for combating
multi-resistant bacteria infections.
The global emergence of antibiotic-resistant strains continues unabated, along with an over-
all increase in the number of infections worldwide, highlighting the urgent need for new agents
to treatMycobacterium and Pseudomonas infections. Non-conventional anti-infective ap-
proaches must be explored. Our findings may provide a new basis for the discovery of new and
potent radical scavenger inhibitors and improved clinical applications of these compounds in
antimicrobial therapy.
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Supporting Information
S1 Fig. A sequence alignment of NrdFs fromM. tuberculosis (Mtub NrdF2),M. bovis subs
bovis (Mbbo),M. bovis BCG strain Pasteur (MboP), Salmonella typhimurium (Styp), E. coli
(Ecol) and B. anthracis (Bant). Iron ligands (ligated iron ion) and tyrosyl radical-harboring
residues are shown.
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